Literature DB >> 8019839

PACAP is a potent and highly effective stimulator of adenylyl cyclase activity in the retinas of different mammalian species.

P Onali1, M C Olianas.   

Abstract

In rat, calf, pig and rabbit retinas the two forms of pituitary adenylate cyclase activating polypeptide with 38- and 27-amino acids (PACAP-38 and PACAP-27) produce a robust stimulation of adenylyl cyclase activity. PACAP-38 acts at picomolar concentrations and is generally more potent than PACAP-27. Both PACAPs are systematically more effective than the structurally homologous vasoactive intestinal peptide. Moreover, rat, calf and pig retinas contain significant amounts of PACAP-38 immunoreactivity. This study provides the first evidence for the action and occurrence of PACAP in mammalian retinas.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8019839     DOI: 10.1016/0006-8993(94)91825-2

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  10 in total

1.  Degree of damage compensation by various PACAP treatments in monosodium glutamate-induced retinal degeneration.

Authors:  Norbert Babai; Tamás Atlasz; Andrea Tamás; Dóra Reglödi; Gábor Tóth; Péter Kiss; Róbert Gábriel
Journal:  Neurotox Res       Date:  2005-11       Impact factor: 3.911

2.  Pituitary adenylate cyclase-activating peptide-immunoreactive nerve fibers in the cat eye.

Authors:  T Elsås; R Uddman; F Sundler
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1996-09       Impact factor: 3.117

3.  Vasoactive neuropeptides in clinical ophthalmology: An association with autoimmune retinopathy?

Authors:  Donald R Staines; Ekua W Brenu; Sonya Marshall-Gradisnik
Journal:  Clin Ophthalmol       Date:  2009-06-02

Review 4.  Neuropeptides and diabetic retinopathy.

Authors:  Robert Gábriel
Journal:  Br J Clin Pharmacol       Date:  2013-05       Impact factor: 4.335

5.  Effects of pituitary adenylate cyclase activating polypeptide (PACAP) on the PKA-Bad-14-3-3 signaling pathway in glutamate-induced retinal injury in neonatal rats.

Authors:  Boglárka Rácz; Ferenc Gallyas; Péter Kiss; Andrea Tamás; Andrea Lubics; István Lengvári; Erzsébet Röth; Gábor Tóth; Orsolya Hegyi; Zsófia Verzál; Csaba Fabricsek; Dóra Reglódi
Journal:  Neurotox Res       Date:  2007-09       Impact factor: 3.911

Review 6.  PACAP and NAP: Effect of Two Functionally Related Peptides in Diabetic Retinopathy.

Authors:  Agata Grazia D'Amico; Grazia Maugeri; Giuseppe Musumeci; Dora Reglodi; Velia D'Agata
Journal:  J Mol Neurosci       Date:  2021-01-05       Impact factor: 3.444

Review 7.  Emerging Role of PACAP as a New Potential Therapeutic Target in Major Diabetes Complications.

Authors:  Rubina Marzagalli; Soraya Scuderi; Filippo Drago; James A Waschek; Alessandro Castorina
Journal:  Int J Endocrinol       Date:  2015-05-14       Impact factor: 3.257

8.  Distribution and protective function of pituitary adenylate cyclase-activating polypeptide in the retina.

Authors:  Tomoya Nakamachi; Attila Matkovits; Tamotsu Seki; Seiji Shioda
Journal:  Front Endocrinol (Lausanne)       Date:  2012-11-23       Impact factor: 5.555

9.  The PACAP-derived peptide MPAPO facilitates corneal wound healing by promoting corneal epithelial cell proliferation and trigeminal ganglion cell axon regeneration.

Authors:  Zixian Wang; Wailan Shan; Huixian Li; Jia Feng; Shiyin Lu; Biqian Ou; Min Ma; Yi Ma
Journal:  Int J Biol Sci       Date:  2019-10-15       Impact factor: 6.580

10.  Does autoimmunity of endogenous vasoactive neuropeptides cause retinopathy in humans?

Authors:  Donald R Staines
Journal:  Med Hypotheses       Date:  2007-06-07       Impact factor: 1.538

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.